Genmab A/S Files 6-K for Incorporation by Reference
Ticker: GNMSF · Form: 6-K · Filed: Apr 16, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
TL;DR
Genmab A/S filed a 6-K, mostly procedural, to update its S-8 filings. No new material info.
AI Summary
Genmab A/S filed a Form 6-K on April 16, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing does not contain new financial information but serves to update or supplement previously filed documents.
Why It Matters
This filing ensures that Genmab A/S's registration statements remain current by incorporating this report, which is standard practice for companies with ongoing stock-based compensation plans.
Risk Assessment
Risk Level: low — The filing is a routine administrative update and does not introduce new financial risks or material changes to the company's operations.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 001-38976 (other) — SEC File Number
- 333-232693 (other) — Form S-8 File Number
- 333-253519 (other) — Form S-8 File Number
- 333-262970 (other) — Form S-8 File Number
- 333-277273 (other) — Form S-8 File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on April 16, 2024.
What type of company is Genmab A/S?
Genmab A/S is a foreign private issuer in the pharmaceutical preparations industry.
Under which SEC Act is this report filed?
This report is filed under the Securities Exchange Act of 1934, pursuant to Rule 13a-16 or 15d-16.
Does this filing introduce new financial information or material updates?
No, this filing primarily serves as an incorporation by reference into existing registration statements and does not appear to introduce new financial information or material operational updates.
Filing Stats: 227 words · 1 min read · ~1 pages · Grade level 14.9 · Accepted 2024-04-16 10:07:00
Filing Documents
- tmb-20240416x6k.htm (6-K) — 18KB
- tmb-20240416xex99d1.htm (EX-99.1) — 19KB
- tmb-20240416xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-005159.txt ( ) — 45KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: APRIL 16, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated April 16, 2024: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2024